Krystal Biotech, Inc. Operating Income Loss

• Krystal Biotech, Inc. showed an increase of +145.3% in Operating Income Loss from 2024 to 2025.
• This data is from Krystal Biotech, Inc.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
• XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 10 years of available data (2016 to 2025), Krystal Biotech, Inc.'s Operating Income Loss has grown by 14,211.5%.
• Historical annual values: Fiscal year 2025: $161.30 million | Fiscal year 2024: $65.75 million | Fiscal year 2023: -$109.62 million | Fiscal year 2022: -$145.20 million | Fiscal year 2021: -$68.28 million | Fiscal year 2020: -$33.00 million | Fiscal year 2019: -$22.08 million | Fiscal year 2018: -$11.92 million | Fiscal year 2017: -$4.77 million | Fiscal year 2016: -$1.14 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026